Idarubicin Capsules (Zavedos): Uses, Dosage, Side Effects

About idarubicin

Idarubicin is a potent

anthracycline chemotherapy medicine

primarily used to treat specific types of cancer, including

leukaemia

—a cancer affecting white blood cells—and

breast cancer

when other treatments have failed.

Also known by the brand name

Zavedos®

, it is available in capsule and injection forms. Leukaemia, particularly acute myelogenous leukaemia (AML) in adults, is a key indication for remission induction in both untreated and relapsed or refractory cases. In breast cancer, it serves as a secondary option, often combined with other therapies.

Idarubicin works by interfering with DNA in cancer cells, inhibiting their growth and division. It can be administered alone or in combination regimens with other cytotoxic agents like cytarabine. Official product information emphasizes its role in AML remission induction, with dosing tailored to patient response and tolerance.

Key Information on Idarubicin

Type of medicine	Used for	Also called	Available as
An anthracycline chemotherapy medicine	Treatment of leukaemia (e.g., AML) and breast cancer	Zavedos®	Capsules and injection

Prior to starting treatment, patients receive detailed information from their doctor and the manufacturer’s leaflet, outlining usage and potential side effects. Treatment is overseen by specialists experienced in oncology, ensuring precise dosing based on body surface area (mg/m²).

How to take idarubicin

**Swallow idarubicin capsules whole** with a glass of water—do not bite, chew, suck, or open them, as this can release the drug prematurely and increase side effects. Timing is flexible: take before food or after a light meal, but aim for the

same time each day

to maintain consistency.

Dosage is individualized by a specialist. For AML induction, common regimens include

12 mg/m² daily for three days

via slow IV injection (10-15 minutes), combined with cytarabine 100 mg/m² continuous infusion over seven days. Oral capsules follow similar principles, with labels specifying exact doses. Courses may be single-dose or multi-day, potentially repeated after weeks if needed.

A second course may be given if leukaemia persists, but delay if severe mucositis occurs, reducing the dose by 25% upon recovery. Always follow the prescribed label; contact your doctor for uncertainties.

• Key administration tips: Water helps swallowing; avoid crushing.
• Treatment duration varies: 1-3 days initially, with monitoring for repeats.
• Combination therapy common in AML.

Getting the most from your treatment

Regular appointments with your doctor or hospital are essential for monitoring progress via

frequent blood tests and check-ups

. Idarubicin causes

myelosuppression

, lowering white blood cell counts and raising infection risk—neutrophils are most affected, with nadirs at 10-14 days post-dose.

To minimize risks:

• Avoid contact with infected individuals.
• Report symptoms like sore throat, fever, or chills immediately.
• Maintain hand hygiene and avoid crowds during low blood counts.
• Liver/kidney function tests (bilirubin, creatinine) are required before and during therapy.

Cumulative doses up to 400 mg/m² via capsules show low cardiotoxicity risk, but heart function monitoring is advised. Precautions reduce severe complications like infections or bleeding.

Can idarubicin cause problems?

While effective, idarubicin carries side effects due to its cytotoxic nature. Your doctor discusses these beforehand; not everyone experiences them.

Myelosuppression

is universal, causing leucopenia, neutropenia, thrombocytopenia, and anaemia—life-threatening infections or bleeding possible during nadirs.

Common Side Effects and Management

Side Effect	Description	Action
Diarrhoea, nausea, sore mouth	Most frequent; mucositis 3-10 days post-dose	Speak to doctor; antiemetics help
Increased infection risk	Due to low white cells	Precautions; report fever
Hair loss, rash, appetite loss	Common dermatological/GI effects	Manage supportively
Anaemia, bleeding, heart issues	Blood count drops; rare CHF	Doctor monitors
Red urine	Harmless, lasts 1-2 days	No action needed

Other effects include abdominal pain, vomiting, oesophagitis, fever, chills, and elevated liver enzymes. Severe GI toxicity (<5% WHO Grade 4) may involve enterocolitis or perforation—monitor for intense pain. Skin issues like alopecia, rash, or radiation recall occur.

Contraindications: Avoid in severe renal/liver impairment, recent MI, arrhythmias, uncontrolled infections, or hypersensitivity. Report new symptoms to your doctor/pharmacist.

Frequently Asked Questions (FAQs)

Q: What cancers does idarubicin treat?

A: Primarily acute myelogenous leukaemia (AML) in adults for remission induction, and breast cancer after other treatments fail.

Q: Does idarubicin change urine color?

A: Yes, it may turn urine red temporarily (1-2 days)—this is normal and harmless.

Q: How is the dose determined?

A: Based on body surface area (e.g., 12 mg/m²/day for 3 days in AML combos); specialist calculates and labels it.

Q: What precautions reduce infection risk?

A: Avoid sick people, practice hygiene, report fever/sore throat; blood tests monitor counts.

Q: Are there heart risks?

A: Possible cardiotoxicity at high cumulative doses; low risk up to 400 mg/m² capsules. Monitor LVEF/ECG.

Q: Can I eat before taking capsules?

A: Yes, before food or after light meal; swallow whole with water.

This FAQ section addresses common patient concerns for better adherence and safety.

Additional Patient Guidance

Idarubicin hydrochloride, the active ingredient, is an orange-red powder in 5 mg or 10 mg capsules. For optimal outcomes, adhere strictly to schedules. In AML, second courses require toxicity recovery. Supportive care like antiemetics prevents dehydration from nausea/vomiting.

Pregnancy/breastfeeding: Contraindicated due to fetal risks—use contraception. Store securely away from children.

Expand on monitoring: Weekly bloods during nadir periods. If CHF develops, manage with digitalis, diuretics, rest. Official Australian PI reinforces dose adjustments for organ impairment.

Clinical Considerations for Healthcare Providers

Though patient-focused, note: Evaluate hepatic/renal function pre-treatment. Delay doses for severe mucositis. Myelosuppression mandates infection prophylaxis; IV antibiotics for febrile neutropenia.

In combos, cytarabine synergy boosts remission rates in AML. Cumulative monitoring prevents irreversible cardiomyopathy.

Patient-reported outcomes highlight manageable GI effects with prophylaxis, emphasizing education on red urine to avoid alarm.